반응식
Cl.O1CCOCC1.[Cl:8][C:9]1[CH:44]=[CH:43][C:12]([CH2:13][N:14]([CH2:33][CH2:34][NH:35]C(=O)OC(C)(C)C)[C:15]([N:17]2[CH2:22][CH2:21][N:20]([C:23]3[C:24]4[C@H:31]([CH3:32])[CH2:30][CH2:29][C:25]=4[N:26]=[CH:27][N:28]=3)[CH2:19][CH2:18]2)=[O:16])=[CH:11][CH:10]=1>CO>[NH2:35][CH2:34][CH2:33][N:14]([CH2:13][C:12]1[CH:43]=[CH:44][C:9]([Cl:8])=[CH:10][CH:11]=1)[C:15]([N:17]1[CH2:18][CH2:19][N:20]([C:23]2[C:24]3[C@H:31]([CH3:32])[CH2:30][CH2:29][C:25]=3[N:26]=[CH:27][N:28]=2)[CH2:21][CH2:22]1)=[O:16]참가 물질
4
반응물 2
생성물 1
시약·촉매·용매 1
반응 조건
- 온도
- 25 °C
실험 절차
A solution of HCl/dioxane at 0° C. was added to (R)-tert-butyl 2-(N-(4-chlorobenzyl)-4-(5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxamido)ethylcarbamate (40 mg, 0.075 mmol) in MeOH (1 mL). The reaction mixture was stirred at 25° C. for 1 hour. After removal of the solvent, the crude product was purified by preparative HPLC to afford (R)—N-(2-aminoethyl)-N-(4-chlorobenzyl)-4-(5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxamide (32 mg, 90%). MS (ESI) m/e (M+H+) 429.2. 1H NMR: δ=8.56 (s, 1H), δ=7.23-7.56 (dd, 4H), δ=4.51 (s, 2H), δ=3.97-4.19 (m, 4H), δ=3.70 (m, 1H), δ=3.61 (m, 4H), δ=3.40-3.43 (t, 2H), δ=2.96-3.15 (m, 4H), δ=2.42 (m, 1H), δ=1.89 (m, 1H), δ=1.21-1.22 (d, 3H).
후처리
- customAfter removal of the solvent
- customthe crude product was purified by preparative HPLC
출처 및 근거
- ORD 기록
- ord-7cb9ba3d5f2f40e0911ee4270af91c34
- 출처 데이터셋
- uspto-grants-2013_02
- 특허 번호
- US08377937B2
연결된 노트
불러오는 중…